Giapreza(angiotensin ii)
Giapreza (angiotensin ii) is a protein pharmaceutical. Angiotensin ii was first approved as Giapreza on 2017-12-21. It is used to treat hypotension in the USA. It has been approved in Europe to treat hypotension and shock. It is known to target type-2 angiotensin II receptor, proto-oncogene Mas, potassium channel subfamily K member 3, and type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Giapreza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Angiotensin ii acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GIAPREZA | La Jolla Pharmaceutical Company | N-209360 RX | 2017-12-21 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| giapreza | New Drug Application | 2023-01-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypotension | EFO_0005251 | D007022 | I95 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Angiotensin Ii Acetate, Giapreza, La Jolla Pharma | |||
| 11219662 | 2037-01-06 | U-3262 | |
| 9220745 | 2034-12-18 | U-2217, U-2218 | |
| 10028995 | 2034-12-18 | U-2338 | |
| 10493124 | 2034-12-18 | U-2679 | |
| 11096983 | 2034-12-18 | U-3211, U-3212 | |
| 11559559 | 2034-12-18 | U-3514 | |
| 9572856 | 2031-07-18 | U-2221 | |
| 9867863 | 2029-12-16 | U-2231 | |
| 10335451 | 2029-12-16 | U-2581 | |
| 10500247 | 2029-12-16 | U-2680, U-2681 | |
| 10548943 | 2029-12-16 | U-2739, U-2740 | |
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CX: Other cardiac stimulants in atc
— C01CX09: Angiotensin ii
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
HCPCS
No data
Clinical
Clinical Trials
1633 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 62 | 57 | 209 | 220 | 109 | 648 |
| Healthy volunteers/patients | — | — | — | 106 | — | 1 | 3 | 15 | 125 |
| Heart failure | D006333 | HP_0001635 | I50 | 4 | 18 | 27 | 37 | 30 | 111 |
| Essential hypertension | D000075222 | — | I10 | 7 | 18 | 42 | 21 | 6 | 92 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 5 | 6 | 19 | 29 | 9 | 65 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 21 | 10 | 5 | 11 | 42 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 2 | 10 | 8 | 15 | 7 | 38 |
| Chronic renal insufficiency | D051436 | — | N18 | 3 | 3 | 3 | 10 | 13 | 31 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 3 | 2 | 8 | 11 | 6 | 29 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 13 | 1 | 10 | 1 | 2 | 27 |
Show 102 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 8 | — | 1 | 9 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 7 | 3 | — | — | 9 |
| Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | 3 | 6 | — | — | 9 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 7 | 1 | — | 1 | 8 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | — | 3 | 4 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 4 | 1 | — | — | 4 |
| Cerebral hemorrhage | D002543 | — | — | — | 1 | 2 | — | 1 | 4 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | 2 | — | — | 3 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | 3 | 1 | — | — | 3 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 2 | 1 | — | — | 3 |
Show 38 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | — | 7 |
| Aging | D000375 | GO_0007568 | R41.81 | 2 | 3 | — | — | 2 | 6 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 5 | — | — | — | 6 |
| Hematologic neoplasms | D019337 | — | — | 1 | 3 | — | — | — | 4 |
| Fibrosis | D005355 | — | — | 1 | 3 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 3 | 1 | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 2 | 1 | — | — | — | 3 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | 1 | 3 |
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | 1 | — | — | 2 | 3 |
Show 83 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 7 | — | — | — | — | 7 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 2 | — | — | — | 4 | 6 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | — | — | — | — | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 2 | — | — | — | — | 2 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 1 | — | — | — | 1 | 2 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 4 | 4 |
| Vasodilation | D014664 | — | — | — | — | — | — | 3 | 3 |
| Pediatric obesity | D063766 | — | — | — | — | — | — | 2 | 2 |
| Vascular stiffness | D059289 | — | — | — | — | — | — | 2 | 2 |
| Pregnancy-induced hypertension | D046110 | — | O13 | — | — | — | — | 2 | 2 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
| Orthostatic hypotension | D007024 | — | I95.1 | — | — | — | — | 2 | 2 |
| Microcirculation | D008833 | — | — | — | — | — | — | 2 | 2 |
| Neurologic manifestations | D009461 | — | — | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Angiotensin ii |
| INN | angiotensin ii |
| Description | Ile(5)-angiotensin II is an angiotensin II that acts on the central nervous system (PDB entry: 1N9V). It has a role as a human metabolite. It is a tautomer of an Ile(5)-angiotensin II dizwitterion. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 11128-99-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408403 |
| ChEBI ID | 2719 |
| PubChem CID | 172198 |
| DrugBank | — |
| UNII ID | M089EFU921 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Giapreza – Innoviva
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 282,937 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
147 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use